Compile Data Set for Download or QSAR
maximum 50k data
Found 288 Enz. Inhib. hit(s) with all data for entry = 9387
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM404211((2S,5R)-5-(2-cyanophenyl)-1-(2'-methoxy-[1,1'-biph...)
Affinity DataKi: <1.00E+3nMAssay Description:Human GPR43 radioligand binding assay is performed by adding successively in the wells of a 96 well plate (Master Block, Greiner, 786201), 50 ul of c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM408766((2S,5R)-1-(1-(5-chloro-2-nitrophenyl)piperidine-4-...)
Affinity DataKi: <1.00E+3nMAssay Description:Human GPR43 radioligand binding assay is performed by adding successively in the wells of a 96 well plate (Master Block, Greiner, 786201), 50 ul of c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM404212((2S,5R)-5-(2-chlorophenyl)-1-(2'-cyano-4'-methoxy-...)
Affinity DataKi:  1.50E+3nMAssay Description:Human GPR43 radioligand binding assay is performed by adding successively in the wells of a 96 well plate (Master Block, Greiner, 786201), 50 ul of c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM408762((2S,5R)-5-(2-chlorophenyl)-1-(1-(2-cyano-4-nitroph...)
Affinity DataKi:  1.50E+3nMAssay Description:Human GPR43 radioligand binding assay is performed by adding successively in the wells of a 96 well plate (Master Block, Greiner, 786201), 50 ul of c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM408761((2S,5R)-5-(2-chlorophenyl)-1-(1-(4-methyl-2-nitrop...)
Affinity DataKi:  1.50E+3nMAssay Description:Human GPR43 radioligand binding assay is performed by adding successively in the wells of a 96 well plate (Master Block, Greiner, 786201), 50 ul of c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM408767((2S,5R)-5-(2-chlorophenyl)-1-(1-(2-nitrophenyl)pip...)
Affinity DataKi: >2.00E+3nMAssay Description:Human GPR43 radioligand binding assay is performed by adding successively in the wells of a 96 well plate (Master Block, Greiner, 786201), 50 ul of c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM408763( (2S,5R)-5-(2-chlorophenyl)-1-(1-(4-nitrophenyl)pi...)
Affinity DataKi: >2.00E+3nMAssay Description:Human GPR43 radioligand binding assay is performed by adding successively in the wells of a 96 well plate (Master Block, Greiner, 786201), 50 ul of c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM408764((2S,5R)-5-(2-chlorophenyl)-1-(1-(2-fluoro-4-nitrop...)
Affinity DataKi: >2.00E+3nMAssay Description:Human GPR43 radioligand binding assay is performed by adding successively in the wells of a 96 well plate (Master Block, Greiner, 786201), 50 ul of c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM408765( (2S,5R)-5-(2-chlorophenyl)-1-(1-(3-methoxy-4-nitr...)
Affinity DataKi: >2.00E+3nMAssay Description:Human GPR43 radioligand binding assay is performed by adding successively in the wells of a 96 well plate (Master Block, Greiner, 786201), 50 ul of c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM408758( (2S,5R)-5-(2-chlorophenyl)-1-(1-(4-(morpholinosul...)
Affinity DataKi: >2.00E+3nMAssay Description:Human GPR43 radioligand binding assay is performed by adding successively in the wells of a 96 well plate (Master Block, Greiner, 786201), 50 ul of c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM408760((2S,5R)-5-(2-chlorophenyl)-1-(1-(4-(N,N-diethylsul...)
Affinity DataKi: >2.00E+3nMAssay Description:Human GPR43 radioligand binding assay is performed by adding successively in the wells of a 96 well plate (Master Block, Greiner, 786201), 50 ul of c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403752((2S,5R)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-bip...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403763((2S,5R)-5-(2-chlorophenyl)-1-(2'-methyl-[1,1'-biph...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403764((2S,5R)-1-(3-((4-chlorobenzyl)oxy)-5-methoxybenzoy...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403767((2S,5R)-5-(2-chlorophenyl)-1-(2'-fluoro-[1,1'-biph...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403773((2S,5R)-5-(2-chlorophenyl)-1-(4'-methyl-[1,1'-biph...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403786((2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-5-phenetho...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403787((2S,5R)-1-([1,1'-biphenyl]-4-carbonyl)-5-(2-chloro...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403788((2S,5R)-5-(2-chlorophenyl)-1-(3-(3,3-diphenylpropo...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403789((2S,5R)-5-(2-chlorophenyl)-1-(3'-fluoro-[1,1'-biph...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403790((2S,5R)-5-(2-chlorophenyl)-1-(3'-methyl-[1,1'-biph...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403791((2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-5-((4-(met...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403792((2S,5R)-5-(2-chlorophenyl)-1-(3'-methoxy-[1,1'-bip...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403793((2S,5R)-5-(2-chlorophenyl)-1-(3,5-dimethoxybenzoyl...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403794((2S,5R)-5-(2-chlorophenyl)-1-(4-(phenoxymethyl)ben...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403795((2S,5R)-5-(2-chlorophenyl)-1-(4-((2-fluorobenzyl)o...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403796((2S,5R)-1-(3-chloro-5-methoxybenzoyl)-5-(2-chlorop...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403797((2S,5R)-5-(2-chlorophenyl)-1-(4'-fluoro-[1,1'-biph...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM463345(US10781171, Compound 19)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403799((2S,5R)-5-(2-chlorophenyl)-1-(chroman-3-carbonyl)p...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403800((2S,5R)-5-(2-chlorophenyl)-1-(3,5-diethoxybenzoyl)...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403801((2S,5R)-5-(2-chlorophenyl)-1-(3-phenethoxybenzoyl)...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403802((2S)-1-([1,1'-biphenyl]-4-carbonyl)-4-benzyl-5-phe...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403801((2S,5R)-5-(2-chlorophenyl)-1-(3-phenethoxybenzoyl)...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403804((2S,5R)-5-(2-chlorophenyl)-1-(2,2-difluorobenzo[d]...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403805((2S,5R)-5-(2-chlorophenyl)-1-(6-phenylnicotinoyl)p...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM408505((2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-5-(2-metho...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM408506( (2S,5R)-5-(2-chlorophenyl)-1-(3′-methoxy-[1...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM408507((2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-5-(trifluo...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403809((2S,5R)-5-(2-chlorophenyl)-1-(1-(4-methoxyphenyl)-...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403810((2S,5R)-5-(2-chlorophenyl)-1-(4-isopropoxybenzoyl)...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403811((2S,5R)-5-(2-chlorophenyl)-1-(3-((3,5-dimethylisox...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403812((2S,5R)-5-(2-chlorophenyl)-1-(3-methyl-5-(trifluor...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403813((2S,5R)-1-(3-(benzyloxy)benzoyl)-5-(2-chlorophenyl...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403814((2S,5R)-5-(2-chlorophenyl)-1-(3-methoxybenzoyl)pyr...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403815((2S,5R)-5-(2-chlorophenyl)-1-(2-phenylpyrimidine-5...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403816((2S,5R)-5-(2-chlorophenyl)-1-(4-(trifluoromethoxy)...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403817((2S,5R)-5-(2-chlorophenyl)-1-(4-(5-cyclopropyl-1,2...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403818(4-((2S,5R)-2-carboxy-5-(2-chlorophenyl)pyrrolidine...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 2(Homo sapiens (Human))
Epics Therapeutics

US Patent
LigandPNGBDBM403819((2S,5R)-5-(2-chlorophenyl)-1-(4-phenylbutanoyl)pyr...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 288 total ) | Next | Last >>
Jump to: